

2018 ANNUAL REPORT

A Banner Year

Clinical Research
PATHWAYS 

Opening Access. Advancing Treatments.

clinicalresearchpathways.org

2018: A BANNER YEAR

Dear Friends,

2018 was a banner year for Clinical Research Pathways. We acted boldly and with vision, taking significant steps to promote health equity, open access, and advance treatments for all.

Our signature accomplishment was the launch of “Training Minority Clinical Teams: Getting New Quality Medicines to All Americans.” Through this partnership with Morehouse School of Medicine, we are increasing diversity among those who conduct and participate in clinical trials. If we want new medicines to work for everyone, we must involve all populations in the research.

From the beginning, we have been a resource for physicians and their desperately ill patients who want to try experimental treatments via a pathway known as expanded access. To better serve these physicians and patients, in 2018 we updated our website to create one of the most complete sources of information on the Food and Drug Administration Expanded Access program.

Success takes courage and commitment. We demonstrated both this past year with a strategic decision to become Clinical Research Pathways. This new name is more closely aligned with our mission. Equally important, “Clinical Research Pathways” better communicates that mission to our generous supporters. With their help, we are increasing diversity in clinical trials, expanding options for treatments, and changing lives.





MARJORIE A. SPEERS, PH.D.
Executive Director

OUR SIGNATURE INITIATIVE

Everyone should benefit from clinical trials. But because some racial and ethnic groups are underrepresented in clinical research, they benefit less. Most of today's medicines and other therapies are based on data obtained primarily from white clinical trial participants. These results don't necessarily apply to African American and Latino patients. They missed out on the trials—and on opportunities for more effective medicines and better health.

Clinical Research Pathways is determined to address this inequity. With our partner, Morehouse School of Medicine, we're training and mentoring minority physicians as clinical investigators. These trusted physicians will then recruit appropriate African American and Latino patients for clinical trials. Together we will increase diversity in clinical research and open the door to improved health and well-being for all.

DIVERSITY




A RESOURCE FOR PHYSICIANS & PATIENTS

For decades, the Food and Drug Administration (FDA) Expanded Access program has helped make investigational products available to patients who have exhausted all other treatment options and are not able to participate in a clinical trial. FDA approves nearly 99% of requests but, on average, receives fewer than 2,000 per year. One reason: Many patients and physicians are unfamiliar with the program.

Clinical Research Pathways is addressing this knowledge gap on multiple fronts. We conducted a physician needs assessment and, in response to the results, created one of the most comprehensive online resources on options for expanded access. We offered free webinars on requesting expanded access for intermediate-size patient populations, which has the potential to help groups of individuals instead of single patients. And, we developed "Points for Patients to Consider" to assist desperately ill patients and their families as they make some very difficult decisions. We are extremely grateful to GSK (GlaxoSmithKline), Johnson & Johnson, Pfizer, and Robert Wood Johnson Foundation for their support for these efforts.

EXPANDED ACCESS



A BOLD REALIGNMENT

Names matter, especially for organizations. Your name tells people who you are and what you care about. It also helps attract people who share your vision and want to make important contributions—of time, talent, and resources—to make that vision a reality.

For these and other reasons, we made the bold decision to rebrand our organization as Clinical Research Pathways. Our new name underscores our determination to open access and advance treatments for all patients regardless of age, gender, race, ethnicity, and health status. Similarly, our board leadership reflects our commitment to our two main priorities: increasing diversity in clinical trials and serving as a resource on expanded access to investigational treatments.

REBRANDING

Clinical Research PATHWAYS

Opening Access. Advancing Treatments.

